1-8 of 8
Volker Wacheck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients

Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do-Youn Oh, John A. Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1466–1477.
https://doi.org/10.1158/1078-0432.CCR-23-2646
Published: 15 April 2024
View article titled, Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Open the PDF for Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients in another window
Includes: Supplementary data
Journal Articles

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Christopher J. Sweeney, Ivor J. Percent, Sunil Babu, Jennifer L. Cultrera, Bryan A. Mehlhaff, Oscar B. Goodman, David S. Morris, Ian D. Schnadig, Costantine Albany, Neal D. Shore, Paul R. Sieber, Susan C. Guba, Wei Zhang, Volker Wacheck, Gregory P. Donoho, Anna M. Szpurka, Sophie Callies, Boris Kin Lin, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2237–2247.
https://doi.org/10.1158/1078-0432.CCR-21-2326
Published: 01 June 2022
View article titled, Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

James J. Harding, Andrew X. Zhu, Todd M. Bauer, Toni K. Choueiri, Alexander Drilon, Martin H. Voss, Charles S. Fuchs, Ghassan K. Abou-Alfa, Sameera R. Wijayawardana, Xuejing Aimee Wang, Brian A. Moser, Arantxa Uruñuela, Volker Wacheck, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5202–5211.
https://doi.org/10.1158/1078-0432.CCR-18-4010
Published: 03 September 2019
View article titled, A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Open the PDF for A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martinez, Enaksha Wickremsinhe, Aaron Fink, Volker Wacheck, Kathleen N. Moore
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3253–3262.
https://doi.org/10.1158/1078-0432.CCR-17-3421
Published: 15 July 2018
View article titled, A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Open the PDF for A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

Lee S. Rosen, Jonathan W. Goldman, Alain P. Algazi, P. Kellie Turner, Brian Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E. Wooldridge, Michaela Banck
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1910–1919.
https://doi.org/10.1158/1078-0432.CCR-16-1418
Published: 13 April 2017
View article titled, A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Open the PDF for A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

Ling Liu, Wei Zeng, Mark A. Wortinger, S. Betty Yan, Paul Cornwell, Victoria L. Peek, Jennifer R. Stephens, Jonathan W. Tetreault, Jinqi Xia, Jason R. Manro, Kelly M. Credille, Darryl W. Ballard, Patricia Brown-Augsburger, Volker Wacheck, Chi-Kin Chow, Lihua Huang, Yong Wang, Irene Denning, Julian Davies, Ying Tang, Peter Vaillancourt, Jirong Lu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (23): 6059–6070.
https://doi.org/10.1158/1078-0432.CCR-14-0543
Published: 30 November 2014
View article titled, LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
Open the PDF for LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake

Thorsten Fuereder, Thomas Wanek, Pamina Pflegerl, Agnes Jaeger-Lansky, Doris Hoeflmayer, Sabine Strommer, Claudia Kuntner, Friedrich Wrba, Johannes Werzowa, Michael Hejna, Markus Müller, Oliver Langer, Volker Wacheck
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (16): 5322–5332.
https://doi.org/10.1158/1078-0432.CCR-10-1659
Published: 14 August 2011
View article titled, Gastric Cancer Growth Control by BEZ235 <em>In Vivo</em> Does Not Correlate with PI3K/mTOR Target Inhibition but with [<sup>18</sup>F]FLT Uptake
Open the PDF for Gastric Cancer Growth Control by BEZ235 <em>In Vivo</em> Does Not Correlate with PI3K/mTOR Target Inhibition but with [<sup>18</sup>F]FLT Uptake in another window
Includes: Supplementary data
Journal Articles

Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma: Synergistic Inhibition of Human Sarcoma Xenotransplants by a Combination of Mcl-1 Antisense Oligonucleotides with Low-Dose Cyclophosphamide

Christiane Thallinger, Markus F. Wolschek, Helmut Maierhofer, Hans Skvara, Hubert Pehamberger, Brett P. Monia, Burkhard Jansen, Volker Wacheck, Edgar Selzer
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4185–4191.
https://doi.org/10.1158/1078-0432.CCR-03-0774
Published: 24 June 2004
View article titled, Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma: <subtitle>Synergistic Inhibition of Human Sarcoma Xenotransplants by a Combination of Mcl-1 Antisense Oligonucleotides with Low-Dose Cyclophosphamide</subtitle>
Open the PDF for Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma: <subtitle>Synergistic Inhibition of Human Sarcoma Xenotransplants by a Combination of Mcl-1 Antisense Oligonucleotides with Low-Dose Cyclophosphamide</subtitle> in another window